panitumumab (Rx)

Brand and Other Names:Vectibix
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 20mg/mL (100mg/vial)
  • 20mg/mL (200mg/vial)
  • 20mg/mL (400mg/vial)
more...

Colorectal Cancer

Indication

  • Indicated for wild-type RAS (in both KRAS and NRAS) metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use (eg, next-generation sequencing [NGS] kit)
  • Combination therapy: With FOLFOX, as first-line treatment
  • Monotherapy: Following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy

Dose

  • 6 mg/kg IV infusion over 60 minutes (over 90 minutes if dose >1 g) q14Days  
  • Also see Administration

Dosage Modifications

Infusion reactions

  • Mild-moderate (grade 1-2): Reduce infusion rate by 50%
  • Severe (grade 3-4): Terminate infusion; permanently discontinue depending on severity and/or persistence

Dermatologic reactions

  • First occurrence of grade 3 dermatologic reaction: Withhold 1 to 2 doses; if reaction improves to <grade 3, reinitiate at the original dose
  • Second occurrence of grade 3 dermatologic reaction: Withhold 1 to 2 doses; if reaction improves to <grade 3, reinitiate at 80% of the original dose
  • Third occurrence of grade 3 dermatologic reaction: Withhold 1 to 2 doses; if reaction improves to <grade 3, reinitiate at 60% of the original dose
  • Fourth occurrence of grade 3 dermatologic reaction: Permanently discontinue
  • Grade 3 or 4 dermatologic reaction that does not recover to <grade 3: Permanently discontinue

Dosing Considerations

Limitation of use

  • Not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown
  • Prior to treatment initiation, assess RAS mutational status in colorectal tumors and confirm the absence of a RAS mutation

Safety and efficacy not established

Next:

Adverse Effects

>10%

Erythema (65%)

Acneiform dermatitis (57%)

Pruritus (57%)

Hypomagnesemia (39%)

Fatigue (26%)

Abdominal pain (25%)

Paronychia (25%)

Skin exfoliation (25%)

Nausea (23%)

Rash (22%)

Constipation (21%)

Diarrhea (21%)

Vomiting (21%)

Skin fissures (20%)

Cough (14%)

Dermatologic toxicity, Grade 3 and 4 (14% )

Acne (13%)

Peripheral edema (12%)

1-10%

Abdominal pain, Grade 3 and 4 (7% )

Pulmonary embolism, Grades 3 to 5 (7% )

Hypomagnesemia, Grade 3 and 4 (4% )

Angioedema, All grades (3% to 4% )

Complication of infusion, All grades (3% to 4% )

Constipation, Grade 3 and 4 (3% )

Binding antibodies (0.4-3.8%)

Diarrhea, Grade 3 and 4 (2% )

Vomiting, Grade 3 and 4 (2% )

Nausea, Grade 3 and 4 (1% )

Anaphylaxis (1% )

Complication of infusion, Grade 3 and 4 (1% )

Sepsis (1%)

<1%

Pulmonary fibrosis

Frequency Not Defined

Conjunctivitis

Growth of eyelashes

Increased tears

Ocular hyperemia

Mucositis

Stomatitis

Postmarketing Reports

Skin and subcutaneous tissue disorders: Skin necrosis, angioedema

Immune system disorders: Anaphylactoid reaction

Eye disorders: Keratitis/ulcerative keratitis

Life threatening and fatal bullous mucocutaneous disease

Previous
Next:

Warnings

Black Box Warnings

Dermatologic toxicity

  • Dermatologic toxicities, some severe (NCI-CTC grade 3 or higher), related to panitumumab blockade of EGF binding and subsequent inhibition of EGFR-mediated signaling pathways have been reported in patients receiving panitumumab monotherapy
  • Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving monotherapy
  • Clinical manifestations included, but were not limited to, dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures
  • Severe dermatologic toxicities were complicated by infection including sepsis, septic death, and abscesses requiring incisions and drainage
  • It could not be determined whether these mucocutaneous adverse reactions were directly related to EGFR inhibition or to idiosyncratic immune-related effects (eg, Stevens Johnson syndrome or toxic epidermal necrolysis)
  • Withhold or discontinue panitumumab and monitor for inflammatory or infectious sequelae in patients with severe dermatologic toxicities

Contraindications

None

Cautions

Increased tumor progression, increased mortality, or lack of benefit in patients with RAS-mutant mCRC; determine RAS-mutant tumor status in an experienced laboratory using an FDA-approved test before treatment

Monitor patients who develop dermatologic toxicities while receiving panitumumab for the development of inflammatory or infectious sequelae; limit sun exposure

Panitumumab is not indicated for use in combination with chemotherapy due to increase in mortality or toxicity

Permanently discontinue in patients developing pulmonary fibrosis/interstitial lung disease

Monitor for keratitis or ulcerative keratitis; interrupt or discontinue panitumumab for acute or worsening keratitis

Monitor electrolytes and institute appropriate treatment if needed

Terminate the infusion for severe infusion reactions

Ocular toxicities reported; monitor for keratitis or ulcerative keratitis; interrupt or discontinue for acute or worsening keratitis

Discontinue permanently if patient develops interstitial lung disease, pneumonitis, or lung infiltrates

Avoid pregnancy

Not indicated for treatment of patients with colorectal cancer that harbor somatic RAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either KRAS or NRAS (RAS)

Progressively decreasing serum magnesium levels leading to severe (grade 3-4) hypomagnesemia reported; monitor patients for hypomagnesemia and hypocalcemia prior to initiating treatment, periodically during treatment, and for up to 8 weeks after completion of treatment; other electrolyte disturbances, including hypokalemia, have also been observed; replete magnesium and other electrolytes as appropriate

Previous
Next:

Pregnancy & Lactation

Pregnancy

Based on data from animal studies and mechanism of action; therapy can cause fetal harm when administered to pregnant women; limited available data on use of therapy in pregnant women are not sufficient to inform a risk of adverse pregnancy-related outcomes; panitumumab is a human IgG monoclonal antibody and may be transferred across the placenta during pregnancy; advise pregnant women of the potential risk to the fetus

Contraception

  • Females: Therapy can cause fetal harm when administered to a pregnant woman; advise females of reproductive potential to use effective contraception during treatment and for 2 months after last dose

Infertility

  • Females: Based on results from animal fertility studies conducted in female cynomolgus monkeys, therapy may reduce fertility in females of reproductive potential; effects in animal studies were reversible.

Lactation

There are no data on presence of drug in human milk or effects of panitumumab on breastfed infant or on milk production; human IgG is present in human milk, but published data suggest that breast milk antibodies do not enter neonatal and infant circulation in substantial amounts; because of potential for serious adverse reactions in breastfed infants from therapy, advise women not to breastfeed during treatment and for 2 months after final dose

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

Human monoclonal antibody to human EGF receptor

Pharmacokinetics

Peak Plasma Concentration: 213±59 mcg/mL

Trough Concentration: 39±14 mcg/mL

Half-Life, Elimination: 7.5 days

Clearance: 4.9±1.4 mL/kg/day

Pharmacogenomics

Colorectal cancer expressing with KRAS wild-type respond more favorably to regimens that include anti-EGFR antibodies (cetuximab, panitumumab); whereas, the presence of KRAS mutation (codon 12 or 13) showed an absence of biological and clinical activity for the anti-EGFR antibody treatment

Strongly recommended that patients with metastatic CRC who are being considered for treatment with anti-EGFR antibody therapy should be tested for the presence of a KRAS mutation prior to the administration of therapy (NCCN guidelines)

Genetic testing laboratories

  • The following companies are currently offering KRAS mutation status testing
  • Clarient, Inc. (http://www.clarientinc.com)
  • Caris Diagnostics (http://www.carisdx.com)
  • DxS (http://www.dxsdiagnostics.com)
  • Genzyme Genetics (http://www.genzymegenetics.com)
  • LabCorp (http://www.labcorp.com)
  • Response Genetics (http://www.responsegenetics.com)
Previous
Next:

Administration

IV Preparation

Inspect vial; discard if discolored

Some particulate matter may be present, OK to use (will be removed by filter)

Withdraw dose amount & dilute to 100 mL with 0.9% NaCl (if dose >1 g, in 150 mL)

Mix by gentle inversion, do not shake

Final concentration not to exceed 10 mg/mL

Use diluted solution within 6 hr if stored at room temp, or within 24 hr if stored at 2-8°C

IV Administration

For IV infusion only; not for IV push or bolus

Use low-protein-binding 0.2-0.22 micron in-line filter

Flush IV line with 0.9% NaCl before and after administration

Use infusion pump

Doses &lge;1 g: Infuse over 60 min through peripheral line or indwelling catheter; ; if first infusion tolerated, administer subsequent infusion over 30-60 min

Doses >1 g: Infuse IV over 90 min

Storage

Unopened vials

  • Store vials in the original carton under refrigeration at 2-8°C (36-46°F) until time of use
  • Protect from direct sunlight
  • Do not freeze
  • Discard any unused solution remaining in the vial

Diluted solution

  • Room temperature: Administer within 6 hr of preparation
  • Refrigerated (2-8°C [36-46°]): Administer within 24 hr of preparation
  • Do not freeze
Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous